Valeant Buys Female Libido-Drug Maker Sprout for $1 Billion

Updated on

Valeant to Buy Female Libido-Drug Maker Sprout

Valeant Pharmaceuticals International Inc. agreed to pay about $1 billion in cash for Sprout Pharmaceuticals Inc., the U.S. drugmaker that this week received approval to sell a pill for low libido in women.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.